KCM
CLVS

Kingdon Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Kingdon Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-50,000
Closed -$898K – 80
2018
Q4 		$898K Sell
50,000
-151,000
-75% -$3.09M 0.14% 54
2018
Q3 		$5.9M Buy
+201,000
New +$7.78M 0.41% 69
2018
Q1 		– Sell
-60,000
Closed -$4.08M – 146
2017
Q4 		$4.08M Hold
60,000
– – 0.26% 85
2017
Q3 		$4.94M Buy
+60,000
New +$4.76M 0.32% 76

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kingdon Capital Management's CLVS Position: Q1 2019 in Review

Kingdon Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q1 2019, closing a stake of 1,600 shares — an estimated $29K sold.

Kingdon Capital Management first reported a position in CLVS in Q3 2015 and held it in 8 quarters. The position peaked at $17M in Q2 2018. 186 funds tracked by Wall St. Rank hold CLVS as of Q1 2019.

  • Kingdon Capital Management reported no remaining Clovis Oncology, Inc. position as of Q1 2019 after selling out during the quarter.
  • Kingdon Capital Management sold 1,600 Clovis Oncology, Inc. shares in Q1 2019, an estimated $29K.
  • Kingdon Capital Management first reported a position in Clovis Oncology, Inc. in Q3 2015 and held it in 8 quarters.
  • Kingdon Capital Management's Clovis Oncology, Inc. position peaked at $17M in Q2 2018.
  • 186 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2019.

Based on Kingdon Capital Management's 13F filing for Q1 2019, filed 14 May 2019.